Company Interview / Breathing easy as 4D Medical takes lung imaging to the next level

Andreas Fouras of 4DMedical (ASX:4DX) outlines the significant milestones achieved with the company’s breakthrough CT:VQ technology for lung imaging, having received US FDA clearance for its third-generation product. Fouras describes CT:VQ as the first device enabling doctors to see both airflow and blood flow in the lungs without injected contrast agents, targeting a potential US addressable market exceeding $650 million by replacing an estimated one million scans and accessing even larger markets as clinical adoption grows. He highlights a reimbursement rate of $650 per scan and a strategic position to displace traditional nuclear medicine procedures.

Addressing partnerships and competition, Fouras notes the defensive position of 4DMedical (ASX:4DX) with around 110 patents, guarding market leadership against industry giants like GE, Siemens and Canon. The partnership with Philips is described as a differentiator, as Philips no longer sells nuclear imaging hardware, giving both companies an edge by bringing unique, contrast-free perfusion imaging to market. Fouras claims this enables a scalable, zero-touch software platform delivering substantial workflow efficiency to hospitals.

Fouras also identifies the opportunity in the US government’s Pact Act, offering solutions to screen veterans exposed to toxic fumes—potentially reducing a projected $120 billion spend to $4 billion. He describes clinical trials in Australia and the US and underscores a recent portfolio-enhancing acquisition, positioning 4DMedical as the leading player in heart and lung imaging solutions.

You should be aware that companies presenting do so under commercial agreement with AUSBIZ CAPITAL PTY LTD